NEWS
Aimei Vaccine approved for issuing domestic shares with a clear A-share return signal
Aimei Vaccine (06660.HK) issued the latest announcement on August 30, stating that the company has received approval from the China Securities Regulatory Commission to issue non-publicly listed RMB ordinary shares (i.e., domestic shares) to specific entities.
Market analysts believe that Aimei Vaccine's issuance of domestic shares this time is for non-tradable listed shares, with the raised funds targeting onshore RMB capital, indicating a high probability of exiting through A-share listing. This suggests that the company is likely to initiate a plan to return to A-share in the near future, following its H-share listing last October, marking the implementation phase of this strategic move to A-share.
Reviewing briefly, it is easy to find that Aimei Vaccine has achieved significant R&D breakthroughs and progress this year with several innovative vaccines.
On March 8 this year, Aimei Vaccine announced plans to issue non-publicly listed RMB ordinary shares (i.e., domestic shares and/or non-publicly listed foreign shares) based on specific authorizations. The raised funds will be used to construct new production facilities for the EV71-CA16 bivalent hand, foot, and mouth disease vaccine, develop mRNA vaccines for COVID-19 variants (including but not limited to those univalent and multivalent vaccines under study for the Omicron BA.5 variant), develop multivalent pneumococcal conjugate vaccines, and supplement operational funds for general corporate purposes.
In February and March this year, Aimei Vaccine was included in the Hang Seng Composite Index and quickly became a target stock for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, significantly increasing the company's market attention and expanding its investor base.
For investors, especially those in mainland China, what aspects demonstrate the investment value of this leading domestic vaccine company?
Aimei Vaccine currently has eight commercialized vaccine products targeting six diseases (rabies, hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, and meningococcal disease) in the Chinese market. Among these, Aimei Vaccine has established absolute dominance in its hepatitis B and rabies vaccine products.
Based on the 2021 batch issuance volume, Aimei Vaccine is the largest supplier of hepatitis B vaccines globally and in China, as well as the second largest producer of human rabies vaccines globally and in China.
Currently, Aimei Vaccine holds all five validated human vaccine technology platforms globally (i.e., bacterial vaccine platform technology, viral vaccine platform technology, genetic engineering vaccine platform technology, combination vaccine platform technology, and mRNA vaccine platform technology). Particularly in the layout of the mRNA technology platform representing the new generation of vaccine technology, Aimei Vaccine has a strong advantage.
Under the mRNA technology platform, Aimei not only has the first domestically developed bivalent broad-spectrum mRNA vaccine targeting the Omicron BA.5 variant, which has entered Phase III clinical trials, providing strong validation of its platform strength, but also has obtained eight domestic and international clinical approvals for its mRNA technology platform vaccine products. Furthermore, its clinical trial application for the first domestically developed non-COVID mRNA vaccine, namely the mRNA rabies vaccine, has been accepted by the CDE.
In the future, Aimei Vaccine will continue to explosively apply its potential in the race track with a large number of unmet clinical demands for varieties such as RSV and cancer vaccines under the mRNA technology platform.
Moreover, with numerous breakthroughs in the R&D and commercialization of heavyweight products such as the 13-valent pneumococcal polysaccharide conjugate vaccine, tetravalent meningococcal polysaccharide conjugate vaccine, and the EV71-CA16 bivalent hand, foot, and mouth disease vaccine, coupled with capital recognition and support, investors have sufficient reasons to anticipate that Aimei Vaccine will deliver innovative products with higher safety and better immunogenicity to humanity.
It is expected that in five years, Aimei will become a world-class vaccine enterprise with more than 20 approved and listed vaccines, including over eight critical vaccines, truly unleashing the advantages of a top-tier enterprise. As a leading domestic vaccine company, Aimei Vaccine's return to A shares is bound to attract high market attention.
Market analysts believe that Aimei Vaccine's issuance of domestic shares this time is for non-tradable listed shares, with the raised funds targeting onshore RMB capital, indicating a high probability of exiting through A-share listing. This suggests that the company is likely to initiate a plan to return to A-share in the near future, following its H-share listing last October, marking the implementation phase of this strategic move to A-share.
Reviewing briefly, it is easy to find that Aimei Vaccine has achieved significant R&D breakthroughs and progress this year with several innovative vaccines.
On March 8 this year, Aimei Vaccine announced plans to issue non-publicly listed RMB ordinary shares (i.e., domestic shares and/or non-publicly listed foreign shares) based on specific authorizations. The raised funds will be used to construct new production facilities for the EV71-CA16 bivalent hand, foot, and mouth disease vaccine, develop mRNA vaccines for COVID-19 variants (including but not limited to those univalent and multivalent vaccines under study for the Omicron BA.5 variant), develop multivalent pneumococcal conjugate vaccines, and supplement operational funds for general corporate purposes.
In February and March this year, Aimei Vaccine was included in the Hang Seng Composite Index and quickly became a target stock for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, significantly increasing the company's market attention and expanding its investor base.
For investors, especially those in mainland China, what aspects demonstrate the investment value of this leading domestic vaccine company?
Aimei Vaccine currently has eight commercialized vaccine products targeting six diseases (rabies, hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, and meningococcal disease) in the Chinese market. Among these, Aimei Vaccine has established absolute dominance in its hepatitis B and rabies vaccine products.
Based on the 2021 batch issuance volume, Aimei Vaccine is the largest supplier of hepatitis B vaccines globally and in China, as well as the second largest producer of human rabies vaccines globally and in China.
Currently, Aimei Vaccine holds all five validated human vaccine technology platforms globally (i.e., bacterial vaccine platform technology, viral vaccine platform technology, genetic engineering vaccine platform technology, combination vaccine platform technology, and mRNA vaccine platform technology). Particularly in the layout of the mRNA technology platform representing the new generation of vaccine technology, Aimei Vaccine has a strong advantage.
Under the mRNA technology platform, Aimei not only has the first domestically developed bivalent broad-spectrum mRNA vaccine targeting the Omicron BA.5 variant, which has entered Phase III clinical trials, providing strong validation of its platform strength, but also has obtained eight domestic and international clinical approvals for its mRNA technology platform vaccine products. Furthermore, its clinical trial application for the first domestically developed non-COVID mRNA vaccine, namely the mRNA rabies vaccine, has been accepted by the CDE.
In the future, Aimei Vaccine will continue to explosively apply its potential in the race track with a large number of unmet clinical demands for varieties such as RSV and cancer vaccines under the mRNA technology platform.
Moreover, with numerous breakthroughs in the R&D and commercialization of heavyweight products such as the 13-valent pneumococcal polysaccharide conjugate vaccine, tetravalent meningococcal polysaccharide conjugate vaccine, and the EV71-CA16 bivalent hand, foot, and mouth disease vaccine, coupled with capital recognition and support, investors have sufficient reasons to anticipate that Aimei Vaccine will deliver innovative products with higher safety and better immunogenicity to humanity.
It is expected that in five years, Aimei will become a world-class vaccine enterprise with more than 20 approved and listed vaccines, including over eight critical vaccines, truly unleashing the advantages of a top-tier enterprise. As a leading domestic vaccine company, Aimei Vaccine's return to A shares is bound to attract high market attention.
